Astec LifeSciences Limited (NSE:ASTEC)
India · Delayed Price · Currency is INR | Market Cap | 19.60B |
| Revenue (ttm) | 4.03B |
| Net Income (ttm) | -1.28B |
| Shares Out | 22.28M |
| EPS (ttm) | -65.31 |
| PE Ratio | n/a |
| Forward PE | 142.14 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 5,216 |
| Average Volume | 34,633 |
| Open | 871.00 |
| Previous Close | 879.50 |
| Day's Range | 870.00 - 888.80 |
| 52-Week Range | 634.60 - 1,333.50 |
| Beta | 0.17 |
| RSI | 49.34 |
| Earnings Date | Jul 25, 2025 |
About DFS
Astec LifeSciences Limited, together with its subsidiaries, manufactures and sells agrochemical active ingredients and pharmaceutical intermediates in India. The company provides triazole fungicides for use in field crops; foliar treatment for the control of scab, powdery mildew, shot-hole, blossom blight, and rust; seed treatment for the control of seed and soil-borne diseases in cotton and maize, as well as grains, such as barley, rice, and wheat; post-harvest drench; and food additive and wood preservative. It also provides herbicides, insec... [Read more]
Financial Performance
In 2024, Astec LifeSciences's revenue was 3.81 billion, a decrease of -16.86% compared to the previous year's 4.59 billion. Losses were -1.35 billion, 187.1% more than in 2023.
Financial numbers in GBP Financial StatementsNews
Astec LifeSciences shares rise over 4% after Burjis Godrej appointed as Managing Director
Shares of Astec LifeSciences surged 4.58% to Rs 706.15 in Monday’s session after the company appointed Burjis Godrej as Managing Director for a five-year term starting April 1, 2025. Burjis, the elder...